[{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid-based Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IGC-1A","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IGC Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by IGC Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
